Cocktail and Poster viewing Poster Display session

37P - Genomics and pharmacogenomics analyses of cancer cell lines using the CellMinerCDB and CellMiner web-applications (ID 168)

Presentation Number
Lecture Time
18:30 - 18:30
  • W. Reinhold
Hall Bordeaux, Palais des Congrès, Paris, France
18:00 - 18:45
  • W. Reinhold
  • Y. Pommier



Complimentary datasets and functionality that facilitate comparisons of genomic, molecular and pharmacological data within the NCI-60 cancerous cell lines, Cancer Cell Line Encyclopedia (CCLE), Genomics of Drug Sensitivity in Cancer (GDSC), Cancer Therapeutics Response Portal (CTRP), NCI/DTP small cell lung cancer (SCLC), and NCI Almanac cell line sets are provided by the CellMiner ( and CellMinerCDB ( web-applications.


Pharmacogenomics analyses using CellMiner compare the 60 cancerous cell lines of the NCI-60 using five tools, and include 22 data sets. Pharmacogenomics analyses using CellMinerCDB compare the NCI-60, CCLE, GDSC, CTRP, NCI/DTP SCLC, and NCI Almanac cell line data six, using eight tools, and include 29 data sets. Both provide multiple ways to download or query that data, and are described in detail in their respective urls.


Data for the NCI-60, providing the most extensive public set of cell line molecular and drug activity data (generated by the NCI Developmental Therapeutics Program, are made available through CellMiner. The substantially increased cell line numbers and tissue of origin types provided by the CCLE, GDSC, and CTRP are contained in CellMinerCDB. Separate but complimentary functionalities are provided by the two web-applications. Variable numbers and kinds of data types are available for the differing cell line sets. The composition and numbers of cell lines also varies within the different sets, with 60 for the NCI-60, 69 for the SCLC, and ∼1000 for the CCLE, GDSC, and CTRP. One may fill in data gaps by merging data from multiple sources, taking advantage of the partial cell line overlaps that exist between many of these cell line sets. Extended analysis and quality assessment are also made possible by comparisons of data from multiple institutions.


Exploration of the relationships between and among molecular alterations and pharmacological responses in cancer cell lines from the omic perspective is facilitated by this rich set of data and functionalities.

Legal entity responsible for the study

The National Cancer Institute, USA.


Has not received any funding.


All authors have declared no conflicts of interest.